Vasa Therapeutics Announces Closing of Seed Financing led by Orphinic Scientific SA

"We are excited to have led the seed financing for Vasa. The company's novel biomarker strategy can lead to a personalized medicine-based therapy for HFpEF, a highly heterogenous disease, for which the currently available drugs do not provide durable improvement," said Adam Kruszewski, CEO of Orphinic. "We are also pleased to see multiple opportunities for the other Vasa assets, including sarcopenia, obesity, and peripheral artery disease."

 


read more ⬇️

 

Vasa Therapeutics Announces Closing of Seed Financing to Advance Novel Therapies for Diseases of Cardiovascular Aging

 by PR Newswire

 


 by Longevity.Technology

linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram